ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) is set to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect ClearPoint Neuro to post earnings of ($0.19) per share for the quarter. ClearPoint Neuro has set its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.
ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last issued its earnings results on Tuesday, March 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. ClearPoint Neuro had a negative net margin of 92.21% and a negative return on equity of 83.94%. The firm had revenue of $6.81 million for the quarter, compared to analysts’ expectations of $6.40 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ClearPoint Neuro Stock Performance
NASDAQ CLPT opened at $5.87 on Monday. ClearPoint Neuro has a 52 week low of $4.05 and a 52 week high of $9.87. The firm has a 50 day moving average of $6.28 and a two-hundred day moving average of $6.37. The company has a current ratio of 4.87, a quick ratio of 3.80 and a debt-to-equity ratio of 0.47.
Wall Street Analyst Weigh In
Check Out Our Latest Report on ClearPoint Neuro
ClearPoint Neuro Company Profile
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
See Also
- Five stocks we like better than ClearPoint Neuro
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- Transportation Stocks Investing
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
- Airline Stocks – Top Airline Stocks to Buy Now
- Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.